Edina Cenko Shared STRIVE Trial – Intracoronary Alteplase Shows No Advantage in STEMI
Edina Cenko, Chairperson of ESC Working Group on Coronary Pathophysiology and Microcirculation, posted on LinkedIn:
”The STRIVE trial showed that intracoronary alteplase during primary PCI for STEMI with high thrombus burden did not improve MACE, ST-segment resolution or myocardial blush grade compared with placebo, with a signal toward more ventricular fibrillation.
Once more, no adjunctive strategy has yet succeeded in improving downstream microvascular perfusion after epicardial flow is restored. The search for an effective solution in MVO after STEMI continues.”
Read the study here.
Title: Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial
Authors: Shamir R. Mehta, Natalia Pinilla-Echeverri, Denise Tiong, Tanya Kovalova, Tej Sheth, Madhu K. Natarajan, Matthew Sibbald, James L. Velianou, Robert Welsh, Bryan Har, Sanjit S. Jolly, Nicholas Valettas, J.D. Schwalm, Michael Tsang, Rutaba Khatun, Rajibul Mian, Jennifer Cunningham, Eric Ly, Tara McCready, Kevin R. Bainey
Stay updated with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin